Asia-Pacific Translating scientific breakthroughs into products that genuinely impact patients is more challenging than it has ever been. Only ten percent of drugs that enter clinical trials ever make it all the way to patients, meaning that much of the USD 250 billion spent on pharma R&D every year goes towards…
Australia Medicines regulatory agencies face enormous challenges in supporting and maintaining the safety, quality and supply of therapeutic goods in their respective countries and regions. Professor Anthony (Tony) Lawler, head of Australia’s Therapeutic Goods Administration (TGA), took time out from this work to respond to questions regarding the progress that TGA is…
Australia Australia will shortly have its latest national election, and we are again seeing pharmaceuticals being front and centre in the campaign. The starter’s gun has been fired for the 2025 Australian federal election, which will be held on Saturday, 3 May, just 5 days after Canada’s forthcoming national election.…
Asia A whistlestop tour though the latest news from pharma in Asia, taking in the American gene sequencing giant caught in the crosshairs of the US-China tariff row, the ADC-focused Singaporean biotech getting a 187 million dollar funding boost, why the Australian regulator has rejected Eisai’s Alzheimer’s drug, the activist fund…
APAC A roundup of the biggest pharma stories coming out of APAC, including Eisai’s deal with biotech SEED Therapeutics and share drop after Alzheimer’s rejection in the EU; Mayne Pharma’s lawsuit against Sun; Novo Nordisk’s insulin partnership with Bio Farma, and Celltrion’s resturcturing. Amid GLP-1 boom, Novo Nordisk strikes up…
Australia Richard Day of the University of New South Wales, writing in the October 2023 edition of DIA’s Global Forum magazine, looks at updates to the health technology assessment (HTA) processes in Australia and New Zealand In April 2023, the Australian Department of Health and Aged Care launched an independent Health…
Australia After last year’s acquisition of Vifor Pharma, the firm’s largest ever, opened new avenues for diversification, the ground-breaking approval of the Hemgenix gene therapy for Hemophilia B was an equally significant moment for the company. New CEO Paul MacKenzie continues to pursue further growth for Australia’s largest biopharma company, investing…
Global CSL, Australia’s largest biopharma company, overcame the challenges of the pandemic-related decline in plasma collection and has since racked up wins such as the acquisition of Vifor, the largest in the company’s history, and the FDA approval of its gene therapy for haemophilia B. Newly appointed CEO Paul McKenzie takes…
Australia A roundup of some of the latest news from Australian pharma, including CSL’s unification of business units, a workers strike at Pfizer’s manufacturing plant, a new USD 173 million research centre, and a billionaire’s bet on biotech. New $173M research centre for pandemic drug discovery (Endpoints News) In the…
Australia With one of the best healthcare systems in the world, according to the World Health Organisation (WHO), Australia is home to some 250 global and local reasearch-based pharmaceutical companies and ranks 13th in the global share of pharmaceutical patents. Value of the market: Economic footprint of the industry: Acquistions of…
Asia-Pacific Writing in the June edition of DIA’s Global Forum magazine, Ellen Sem, Fengyun (Vicky) Han and Annetta C. Beauregard from Janssen Pharmaceutical Companies of Johnson & Johnson, outline the real-world data (RWD) and real-world evidence (RWE) regulatory landscape in Asia Pacific. Real-world data (RWD) and real-world evidence (RWE) have played an…
Australia Pharmaceutical policy issues played a major role in Australia’s recent national election. Shawview Consulting’s Brendan Shaw outlines the medicines issues that came under scrutiny during the campaign. It was the first national election since the start of the COVID-19 pandemic, and it resulted in an historic change of government. The…
See our Cookie Privacy Policy Here
